Drug maker Bayer AG said Monday it has reached settlements in more than 2,800 cases related to the 2001 withdrawal of a cholesterol-lowering drug, paying nearly $1.1 billion in out-of-court deals.
Bayer pulled Lipobay, marketed as Baycol in the United States, after it was linked to a rare muscle-wasting syndrome and about 100 patient deaths.
In a regular update posted on its Web site, the Leverkusen-based company said it has now reached 2,861 settlements and agreed to pay a total of $1.094 billion without admitting liability. Some 7,577 suits are still pending, it said.
Earlier this year, Bayer reached an agreement with most of its insurers on coverage of around $1.2 billion for litigation related to the Lipobay withdrawal.